🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 09074F207 (prev. 09074F108 )
- Market Cap
- Small Cap
- IPO
- 9/18/2020 · $10/share
Business: BioVie Inc. is a clinical-stage company developing innovative drug therapies for liver disease. BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s).
Notes: August 12, 2019 -- BioVie Inc., a Nevada corporation, filed a notice of termination regarding an amendment to its Articles of Incorporation intended to effect a reverse split of its Class A common stock as a result of its Board of Directors having determined not to proceed with the contemporaneous public offering and listing on the Nasdaq Capital Market due to market conditions at this time.
Company Contact
- CEO
- Cuong Do
- CFO
- Wendy Kim
- Headquarters
- 680 W Nye Lane Suite 204, Carson City, NV 89703
- Phone
- 775-888-3162
- Investor Relations
- Bruce Mackle, LifeSci Advisors · bmackle@lifesciadvisors.com